BRIEF: Joinn Lab swings to red on lower revenue, falling gross margin
Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), said on Wednesday its revenue fell 15.5% to 486 million yuan ($68.3 million) in the third quarter,…
FAST NEWS: Joinn Laboratories spents $3.7 million on share buyback
The Latest: Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), said on Monday that since announcing a plan on Mar. 27 to repurchase its A…
FAST NEWS: Joinn Lab profit plunges, sending shares to 52-week low
The latest: Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), announced on Tuesday it expects to report a net profit of 311 million ($43.8…
FAST NEWS: Joinn Lab profit slumps on falling lab monkey prices
The latest: Joinn Laboratories (China) Co. Ltd. (6127.HK; 603127.SH), China’s leading non-clinical contract research organization (CRO), announced on Monday its revenue rose 15.1% to 575 million yuan ($78.6 million) in the third quarter,…
Joinn profits slide as lab monkey build-up backfires
The leading provider of pre-clinical drug research has predicted its first-half profits will plummet between 70% and 80% due to the falling value of its lab animals Key Takeaways: Joinn…
Cash-strapped Viva Biotech sells stake and plans spinoff
The biotech has gained a capital injection from Temasek and a major Chinese investor, but the deal has not boosted investor confidence Key Takeaways： As well as tapping strategic investors,…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
